Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04855253
Other study ID # 2020LS100
Secondary ID MT2020-27
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date June 9, 2021
Est. completion date December 2024

Study information

Verified date July 2023
Source Masonic Cancer Center, University of Minnesota
Contact Cancer Center Clinical Trials Office
Phone 612-676-4200
Email ccinfo@umn.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single institution Phase I study to determine the maximum tolerated dose (MTD) of E7777 when given prior to cyclophosphamide/fludarabine (CY/Flu) lymphodepletion (LD) chemotherapy and Kymriah, a commercial tisagenlecleucel product, for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are at a higher risk for failure of CAR-T therapy.


Description:

E7777 is a recombinant fusion toxin consisting of full-length human IL-2 fused to the catalytic domains of diphtheria toxin. This trial is designed to augment lymphodepletion prior to CAR-T cells by administration of a targeted immunotoxin against CD25-expressing T-cells. CD25 is expressed at high levels on Tregs but also on activated effector T cells. The use of the CAR-T cell product and associated apheresis and LD chemotherapy is considered standard of care (SOC).


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Diagnosis of a relapse or refractory (r/r) large B cell lymphoma, for which treatment with Kymriah is planned, including: - diffuse large B-cell lymphoma (DLBCL) not otherwise specified, - high grade B-cell lymphoma - DLBCL arising from follicular lymphoma - Considered at high risk for progression after CAR-T therapy by meeting one or more of the following factors: - refractory to last line of therapy - myc over expression >40% in any prior biopsy - =2 sites of extranodal disease - Received two or more lines of systemic therapy - Has secured insurance coverage for Kymriah administration either in the outpatient or inpatient setting. - Age 18 years or older at the time of signing consent. - ECOG performance status of 0, 1, or 2 - Adequate bone marrow reserve defined as: - Absolute neutrophil count (ANC) > 1,000/mm^3 - Platelets = 50,000/mm^3 (transfusion support can be provided) - Hemoglobin >8.0 mg/dl (transfusion support can be provided) Bone marrow involvement at disease assessment is an exclusion as these patients are at an increased risk of severe CRS and/or neurotoxicity - Adequate organ function at enrollment and within 14 days of planned E7777 treatment including: - renal function: eGFR = 50 mL/min/1.73 m^2 - liver function: ALT = 3 times the upper limit of normal (ULN) for age, AST = 3 times the ULN, total bilirubin = 2.0 mg/dl with the exception of patients with Gilbert syndrome; may be included if their total bilirubin is = 3.0 x ULN and direct bilirubin = 1.5 x ULN (if liver is involved by lymphoma, the exception are allowed upon approval of PI) - albumin = 3.0 g/dl - Must have a minimum level of pulmonary reserve defined as = Grade 1 dyspnea (CTCAE v5) and pulse oxygenation SpO2 > 91% on room air. Pulmonary function tests within 28 days of enrollment: >50% corrected DLCO and FEV1 - Hemodynamically stable and LVEF = 50% confirmed by echocardiogram or MUGA - Life expectancy =12 weeks in the opinion of the enrolling investigator as documented in the medical record - Women of child bearing potential and sexually active males with partners of child bearing potential must agree to use birth control for at least 30 days after study treatment or at least at least 4 months after the final dose of CY, whichever is longer Female participants: Two forms of birth control, one of which must be a barrier method, for example: use of intrauterine device (IUD) or oral contraceptives, plus a barrier method such as a condom, diaphragm or cervical cap Male participants: If possible to father a child (unless a successful vasectomy with confirmed azoospermia) participant and female partner, must use adequate contraception - Written voluntary consent prior to the performance of any research related tests or procedures Exclusion Criteria: - Pregnant or breastfeeding - Females of childbearing potential must have a blood test or urine study within 14 days prior to study enrollment to rule out pregnancy. All females will be considered to be of childbearing potential unless they are postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause) or have been sterilized surgically (i.e., bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing) - Known bone marrow involvement, if history of bone marrow involvement must have a BM biopsy to rule-out current involvement - Prior allogeneic transplant - Ocular disease or complaints visual acuity impairment, color or shape distortion, or blurred vision - potential participants are required to have an ophthalmological examine as part of screening - Known CNS involvement by malignancy - if clinically suspicious, must be ruled-out by examination of cerebrospinal fluid (CSF) by flow cytometry - Uncontrolled active hepatitis B or hepatitis C - Active or inactive HIV infection - Untreated active bacterial, viral or fungal infection (e.g. blood culture positive = 72 hours prior to enrollment) - History of heart failure or pulmonary edema, evidence of pleural effusion or active lower extremity edema - Uncontrolled unstable angina and/or myocardial infarction within 3 months of enrollment - Investigational medicinal product within the last 7 days prior to apheresis or CAR-T infusion

Study Design


Intervention

Drug:
E7777
E7777 is a recombinant fusion toxin consisting of full-length human IL-2 fused to the catalytic domains of diphtheria toxin. E7777 is preferentially bound to and internalized by cells expressing the high affinity form (CD25+) of the IL-2 receptor.

Locations

Country Name City State
United States University of Minnesota, Masonic Cancer Center Minneapolis Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Masonic Cancer Center, University of Minnesota

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants experiencing dose limiting toxicity events Dose Limiting Toxicity (DLT) is defined as any of the following events based on CTCAE v5 from the 1st infusion of E7777 through 21 days after the administration of tisagenlecleucel (~28 days after E7777).
Grade 4 infusion related reaction (IRR) associated with E7777
Grade 4 or Grade 3 capillary leak syndrome (CLS)
Grade 3 or 4 liver function test abnormality that do not resolve to Grade 3 or 4 non-hematologic toxicity event that occurs after the administration of E7777 and before lymphodepleting therapy
Any adverse event that results in a delay of lymphodepleting therapy for more than 72 hours and attributed to E7777
Any Grade 5 adverse event
28 Days Post E7777 infusion
Secondary Number of participants experiencing adverse events Number of participants experiencing adverse events related to E7777 to determine safety of the E7777 100 days Post E7777 infusion
Secondary Number of participants experiencing disease free survival (DFS) Number of participants experiencing disease free survival (DFS) at 1 year 1 year Post E7777 infusion
Secondary Number of participants experiencing overall survival (OS) Number of participants experiencing overall survival (DFS) at 1 year 1 year Post E7777 infusion
Secondary Number of non-relapse mortality incidents at day 100 Number of participants experiencing non-relapse mortality at day 100 post E7777 infusion 100 days Post E7777 infusion
Secondary Number of Grade 3 or 4 cytokine release syndrome (CRS) incidents Number of participants experiencing Grade 3 or 4 cytokine release syndrome (CRS) after tisagenlecleucel therapy. 28 Days Post E7777 infusion
Secondary Number of Grade 3 or 4 immune effector cell associated neurotoxicity (ICAN) syndrome incidents Number of participants experiencing Grade 3 or 4 immune effector cell associated neurotoxicity (ICAN) syndrome after tisagenlecleucel therapy. 28 Days Post E7777 infusion
See also
  Status Clinical Trial Phase
Recruiting NCT04670029 - Impact of an APA Program on EFS in Patients With Diffuse Large-cell B Lymphoma Treated in 1st Line Phase 3
Active, not recruiting NCT04572763 - Copanlisib Plus Venetoclax in R/R DLBCL Phase 1/Phase 2
Active, not recruiting NCT04526834 - Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma Phase 1
Recruiting NCT03676504 - Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR Phase 1/Phase 2
Recruiting NCT05365659 - IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas Phase 1
Completed NCT03287817 - CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma Phase 1/Phase 2
Enrolling by invitation NCT05645744 - Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
Completed NCT04316624 - A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy Phase 1
Active, not recruiting NCT04555811 - FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL Phase 1
Terminated NCT04189952 - Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma Phase 2
Recruiting NCT01949818 - Treatment of Diffuse Large B Cell Lymphoma Phase 4
Completed NCT01459887 - Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma Phase 3
Completed NCT03242902 - To Decrease Fatigue With Light Therapy Phase 3
Recruiting NCT04104776 - A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas Phase 1/Phase 2
Recruiting NCT05018520 - The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk Phase 3
Withdrawn NCT04052061 - QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma Phase 1
Recruiting NCT05020392 - Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma Phase 3
Recruiting NCT05006716 - A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies Phase 1/Phase 2
Completed NCT03297424 - A Study of PLX2853 in Advanced Malignancies. Phase 1
Recruiting NCT04545762 - Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma Phase 1